Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ëÀå¾Ï ȯÀÚ°¡ ºÎ´ãÇÏ´Â Á÷Á¢ºñ¿ë: 2³â°£ÀÇ ÃßÀûÁ¶»ç¸¦ ÅëÇØ Cost of Colorectal Cancer Care in Korea: A Prospective Group Study with a 2-year Follow-up

´ëÇÑ´ëÀåÇ×¹®ÇÐȸÁö 2008³â 24±Ç 5È£ p.357 ~ 366
Ãֱͼ±, ¹ÚÀºÃ¶, Àӹΰæ, ÀÓÁøÈ­, ±è¼º°æ, ¹ÚÀçÇö, Á¤½Â¿ë, ¹ÚÁö¿ø, ÀÓ¼®º´, ÃÖÈ¿¼º, Á¤°æÇØ, ±è´ë¿ë, ¹ÚÀç°©,
¼Ò¼Ó »ó¼¼Á¤º¸
Ãֱͼ± ( Choi Kui-Son ) 
±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷´Ü

¹ÚÀºÃ¶ ( Park Eun-Cheol ) 
±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷´Ü
Àӹΰæ ( Lim Min-Kyung ) 
±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷´Ü
ÀÓÁøÈ­ ( Lim Jin-Hwa ) 
±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷´Ü
±è¼º°æ ( Kim Sung-Gyeong ) 
±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷´Ü
¹ÚÀçÇö ( Prk Jae-Hyun ) 
±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷´Ü
Á¤½Â¿ë ( Jeong Seung-Yong ) 
±¹¸³¾Ï¼¾ÅÍ ´ëÀå¾Ï¼¾ÅÍ
¹ÚÁö¿ø ( Park Ji-Won ) 
±¹¸³¾Ï¼¾ÅÍ ´ëÀå¾Ï¼¾ÅÍ
ÀÓ¼®º´ ( Lim Seok-Byung ) 
±¹¸³¾Ï¼¾ÅÍ ´ëÀå¾Ï¼¾ÅÍ
ÃÖÈ¿¼º ( Choi Hyo-Seong ) 
±¹¸³¾Ï¼¾ÅÍ ´ëÀå¾Ï¼¾ÅÍ
Á¤°æÇØ ( Jung Kyung-Hae ) 
±¹¸³¾Ï¼¾ÅÍ ´ëÀå¾Ï¼¾ÅÍ
±è´ë¿ë ( Kim Dae-Yong ) 
±¹¸³¾Ï¼¾ÅÍ ´ëÀå¾Ï¼¾ÅÍ
¹ÚÀç°© ( Park Jae-Gahb ) 
±¹¸³¾Ï¼¾ÅÍ ´ëÀå¾Ï¼¾ÅÍ

Abstract

¸ñÀû: ¾Ï ¹ß»ý°ú »ç¸ÁÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ƯÈ÷ ³²¼º¿¡¼­ ´ëÀå¾Ï ¹ß»ýÀÌ ±Þ°ÝÇÏ°Ô Áõ°¡ÇÏ°í ÀÖ´Ù. º» ¿¬±¸´Â ´ëÀå¾Ï ȯÀÚ°¡ ºÎ´ãÇÏ´Â Á÷Á¢ºñ¿ëÀ» ÃßÁ¤ÇÏ°í, ÀÌ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎÀ» ºÐ¼®ÇÏ¿´´Ù.

¹æ¹ý: ÀÏ°³ º´¿ø ´ëÀå¾Ï¼¾ÅÍ¿¡ ³»¿øÇÏ¿© ´ëÀå¾ÏÀ¸·Î Ä¡·á¹ÞÀº 220¸íÀ» 2³â°£ ÃßÀûÁ¶»ç ÇÏ¿´´Ù. Á÷Á¢ºñ¿ëÀº 3°³¿ù¸¶´Ù ȯÀÚ¿ÍÀÇ ÀÎÅͺä, ÀÇ·áºñ û±¸ÀÚ·á, Àǹ«±â·ÏÁ¶»ç·Î Ãß°èÇÏ¿´´Ù. ·Î±×ġȯµÈ ¼±Çüȸ±ÍºÐ¼®À¸·Î Á÷Á¢ºñ¿ë¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎÀ» ÆľÇÇÏ¿´´Ù.

°á°ú: 220¸íÀÇ ´ëÀå¾Ï ȯÀÚÁß 100¸íÀº °áÀå¾Ï, 120¸íÀº Á÷Àå¾ÏÀ̾ú´Ù. ´ëÀå¾Ï ȯÀÚÀÇ Áø´ÜÈÄ 1³â°£ ÁöÃâÇÑ Á÷Á¢ºñ¿ëÀº 16,280,000¿øÀ̾úÀ¸¸ç, 2³â° ºñ¿ëÀº 5,786,000¿øÀ̾ú´Ù. ÀÌÁß ÀÇ·áºñ°¡ 62¡­68%¸¦ Â÷ÁöÇÏ¿´À¸¸ç, ÀÇ·áºñ Áß º¸ÇèÀÚ ºÎ´ã±ÝÀº 50%¿´´Ù. ȯÀÚÀÇ Áø´Ü ´ç½Ã º´±â, À§Ä¡, Ä¡·áÀ¯Çü, Àç¹ß ¿©ºÎ°¡ Á÷Á¢ºñ¿ë¿¡ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ¿µÇâÀ» ¹ÌÃÆ´Ù.

°á·Ð: ´ëÀå¾Ï ȯÀÚÀÇ Áø´Ü ÈÄ 1³â°£ Á÷Á¢ºñ¿ëÀº 16,280,000¿øÀ¸·Î ȯÀÚÀÇ °æÁ¦Àû ºÎ´ãÀÌ Å« °ÍÀ¸·Î Á¶»çµÇ¾ú´Ù. ±×·¯³ª Á¶±â ´ëÀå¾ÏÀº ÁøÇà¾Ï¿¡ ºñÇØ 2¹è ÀÌ»ó Á÷Á¢ºñ¿ëÀÌ °¨¼ÒÇÏ¿´´Ù.

Purpose: The incidence of cancer incidence and the rate of mortality are increasing in Korea. Specifically, colorectal cancer in men is one of the most sharply increasing malignancies. The objective of this study was to assess the direct costs for colorectal cancer patients and to identify the factors that influence cancer costs.

Methods: The direct costs of colorectal cancer were examined with a prospective group study at a hospital. The direct costs were assessed every 3 months over a 24-month period through patient interviews, medical records, and claims data. We identified the major factors associated with the cost of colorectal cancer by using a general linear model for the log-transformed data.

Results: The group was comprised of 100 patients with colon cancer and 120 patients with rectal cancer. The average costs per patient during the first and the second years after diagnosis were £Ü16,280,000 and £Ü5,786,000, respectively. Medical costs accounted for about 68% (£Ü11,090,000) of the first year¡¯s total cost and about 62% (£Ü3,602,000) of the second year¡¯s total cost. National Health Insurance (NHI) paid approximately 50% of the total medical cost. The total cost of colorectal cancer was clearly associated with the stage of the disease at first diagnosis, the cancer site, therapeutic modalities, and recurrence.

Conclusions: These results indicate that colorectal cancer has a heavy financial impact on cancer patients. The total cost of colorectal cancer is clearly associated with the stage of the disease at first diagnosis. Increased efforts in terms of prevention and early detection may assist in reducing the costs. J Korean Soc Coloproctol 2008;24:357-366

Å°¿öµå

´ëÀå¾Ï;ºñ¿ë;ÄÚȣƮ
Colorectal cancer;Cost;Cohort study

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS